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ABSTRACT 
Colorectal cancer (CRC) is the second leading cause of cancer-related death in Europe and 
the United States. Survival is strongly related to stage at diagnosis and population-based 
screening reduces CRC incidence and mortality.  Stratifying the population by risk offers the 
potential of improving the efficiency of screening.  In this systematic review we searched 
Medline, EMBASE and the Cochrane Library for primary research studies reporting or 
validating models to predict future risk of primary CRC for asymptomatic individuals. 12,808 
papers were identified from the literature search and nine through citation searching.  52 risk 
models were included.  Where reported (n=37), half the models had acceptable-to-good 
discrimination (c-statistic>0.7) in the derivation sample. Calibration was less commonly 
assessed (n=21), but overall acceptable. In external validation studies, 10 models showed 
acceptable discrimination (c-statistic 0.71-0.78). These include two with only three variables 
(age, gender and BMI; age, gender and family history of CRC).  A small number of 
prediction models developed from case-control studies of genetic biomarkers also show some 
promise but require further external validation using population-based samples. Further 
research should focus on the feasibility and impact of incorporating such models into 
stratified screening programmes.  
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INTRODUCTION 
Colorectal cancer (CRC) is the second leading cause of cancer-related death in Europe 
and the United States(1). Survival is strongly related to stage at diagnosis(2) and population-
based screening has been shown to significantly reduce CRC incidence and mortality(3–6).   
Stratifying the population into risk categories offers the potential to improve the efficiency of 
this screening by tailoring the intensity of screening, or preventive approaches, to the 
predicted level of risk. Providing patients and practitioners with a personalised risk 
assessment may also encourage engagement in risk reducing behaviours, including 
participation in screening or prevention programmes and lifestyle changes to reduce 
incidence of disease(7).  
A number of risk prediction models for CRC have been developed and two previous 
reviews of these have been published(8, 9). However, neither was comprehensive, and since 
those reviews were published several new risk models have been developed. This paper 
provides the first comprehensive analysis of risk prediction tools for risk of primary 
colorectal cancer in asymptomatic individuals within the general population.  It includes 
analysis of the range of 87 variables in addition to genes and SNPs included in each model, 
the predictive ability of the different risk models and their potential applicability and practical 
use for population based stratification.  
 
MATERIALS AND METHODS 
We performed a systematic literature review following an a priori established study protocol 
(available on request). 
 
Search strategy 
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We performed an electronic literature search of Medline, EMBASE and the Cochrane 
Library from Jan 2000 up to March 2014  with no language limits using a combination of 
subject headings incorporating ‘colorectal cancer’, ‘risk/risk factor/risk assessment/chance’ 
and ‘prediction/model/score’ (see Supplementary File 1 for complete search strategy for 
Medline and EMBASE).  We then manually screened the reference lists of all included 
papers. 
 
Study selection 
We included studies if they fulfilled all of the following criteria: (i) published as a 
primary research paper in a peer-reviewed journal; (ii) identify risk factors for developing 
colon, rectal or colorectal cancer or advanced colorectal neoplasia at the level of the 
individual; (iii) provide a measure of relative or absolute risk using a combination of two or 
more risk factors that allows identification of people at higher risk of colon and/or rectal 
cancer; and (iv) are applicable to the general population. Studies including only highly 
selected groups, for example immunosuppressed patients, organ transplant recipients or those 
with a previous history of colon and/or rectal cancer were excluded.  Conference proceedings 
were also excluded after contacting the authors to confirm the results had not been published 
elsewhere in a peer-reviewed journal.  
One reviewer (JUS) performed the search and screened the titles and abstracts to 
exclude papers that were clearly not relevant.  Two reviewers (FW and SG) independently 
assessed a random selection of 5% of the papers each.  The full text was examined where a 
definite decision to reject could not be made based on title and abstract alone.  At least two 
reviewers (JUS and FW/SG/JE) independently assessed all full-text papers, and those deemed 
not to meet inclusion criteria by both researchers were excluded.  We discussed papers for 
which it was unclear whether or not the inclusion criteria were met at consensus meetings. 
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Papers written in languages other than English were translated into English for assessment 
and subsequent data extraction.  
 
Data extraction and synthesis 
Data were extracted independently by at least two researchers (JUS and FW/SG/JE) 
using a standardised form to minimise bias. The form included details on: (i) the development 
of the model, including potential risks of bias such as the study design, selection of 
participants, and the variables considered for inclusion in the model and how they were 
selected; (ii) the risk model itself, including the variables included and requirement for data 
collection; (iii) the performance of the risk model in the development population; and (iv) any 
validation studies of the risk model and/or data collection tool, including the study design and 
performance of the risk model.  In this process the methods of studies published for each risk 
model were classified according to the TRIPOD guidelines(10) and tabulation of the methods 
allowed assessment of bias. For studies which included multiple different models, for 
example separate models for men and women or for self-assessment and physician 
assessment, all were included separately.   
 
RESULTS 
Identified risk models  
After duplicates were removed, the search identified 12,808 papers.  Of these, 12,727 
were excluded at title and abstract level and a further 50 after full-text assessment.  After title 
and abstract screening by the first reviewer (JUS), no additional papers met the inclusion 
criteria in the random 10% screened by a second reviewer (FW/SG).  The most common 
reasons for exclusion at full-text level were that the papers included symptomatic 
populations, were conference abstracts or did not include a risk score (Figure 1). Four were 
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excluded as they included circulating biomarkers that were felt to detect prevalent 
undiagnosed disease rather than estimate future risk(11–14).  
 Nine further papers were identified through citation searching, giving 40 papers 
describing 52 risk models for inclusion in the analysis and 6 external validation studies(15–
20).  Table 1 summarises these 52 risk models. Thirteen have advanced colonic neoplasia 
(defined as invasive cancer, an adenoma 10mm or more, a villous adenoma (at least 25% 
villous), or an adenoma with high grade dysplasia) as the outcome(21–32), 13 colon 
cancer(33–41), 20 colorectal cancer (CRC)(31, 36, 38, 39, 41–54), and 6 rectal cancer(37–
39).  Most include both men and women, but 16 are specific to either men or women.  Six 
include only variables that are available in routine medical records. The majority (n=32) 
include variables obtained via a self-completed questionnaire.  These range from 
questionnaires with only one or two simple questions concerning family history(26, 27, 32, 
50, 52), diet(44) or physical activity(38) to those including detailed dietary habits, 
aspirin/NSAID use, oestrogen and HRT use, inflammatory bowel disease, previous 
colonoscopy or sigmoidoscopy and polyp history and the most complex including 15 
variables(35).  Six, all from the same study, use data from a self-completed questionnaire and 
results of blood tests for fasting plasma glucose and total cholesterol(39), four a blood test 
alone for genetic biomarkers(45, 48, 49, 51), and four a self-completed questionnaire and 
genetic biomarkers(43, 54, 46).  Between them, the authors of the 52 risk models considered 
87 different risk factors (Table 2).  
 
Development of the risk models 
Further details of the development of each model and the risks of bias are given in 
Supplementary Tables 1a-d.  Seventeen were developed from case-control studies with cases 
identified from hospitals or cancer disease registries and controls from primary care (n=1), 
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hospitals (n=5), other research studies (n=2), random-digit dialling (n=7), spouses (n=1), 
healthy individuals or blood donors (n=1).  Seventeen were developed from cohort studies 
with between 21,581 and 1,326,058 participants and most identifying cases of cancer through 
cancer registries over a 10-20 year follow-up period. Fourteen were cross-sectional studies of 
participants attending for screening colonoscopy and all but one had advanced colorectal 
neoplasia as the outcome.  Three risk models were developed from a review of the 
literature(35), a meta-analysis of risk factors(47) or modelling in a simulated population(54).  
 
Discrimination of the risk models 
The performance of 42 of the 52 models was reported in at least one of either the 
development population (n=31), using bootstrapping or cross-validation (n=13), a subset of 
the initial development population (n=3), or an external population (n=21). Details of the 
discrimination, calibration and accuracy are given in Table 3 and details of the methods for 
those using a subset of the initial population or external populations in Supplementary Table 
2.   
Discrimination, as measured by the area under the receiver operator curve (AUROC), 
was reported for 37 of the risk models, and these values are summarised in Figure 2 in which 
the models are grouped into five groups according to the type of variables included (routine 
data only, self-completed questionnaire, self-completed questionnaire and non-genetic 
biomarkers, genetic biomarkers, and self-completed questionnaires plus genetic biomarkers). 
Within each group the models are order according to the number of variables included. The 
models on the left are, therefore, those with the fewest and most easily obtained variables and 
the more complex models are towards the right of the figure.  Most models have acceptable 
to good discrimination with AUROCs between 0.65 and 0.75.   
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Amongst those models including only routinely available data, the best performing 
and validated model for advanced colorectal neoplasia was developed by Betes et al among 
2,210 asymptomatic individuals attending routine CRC screening in Spain(21). It includes 
only age, gender and BMI and has AUROCs of 0.65 (95%CI: 0.61-0.69) and 0.71 (95%CI: 
0.64-0.78) in external validation studies in China(22, 24). The only risk scores using routine 
data for colon cancer and CRC were developed by Driver et al from a cohort of 21,581 men 
in the USA(36). The score for colon cancer includes age, BMI and history of smoking and 
has an AUROC of 0.72 in that population and the score for CRC includes those variables plus 
alcohol consumption and has similar discrimination in bootstrap analysis 
(AUROC=0.69)(36).  
The second group of risk models used self-completed questionnaire and, as illustrated 
by the absence of any clear trend in the AUROC within that group in Figure 2, there is no 
clear improvement in discrimination as increasing numbers of variables are added from self-
completed questionnaires to routine data.  These is a suggestion from the third group of risk 
models that adding fasting serum glucose and total cholesterol to self-completed 
questionnaire variables might improve the discrimination in the scores developed by Shin et 
al using a South Korean population of men(39), but this same improvement above other risk 
models containing only routine or questionnaire data was not seen in women.   
The two models with the highest discrimination are both in the group based entirely 
on genetic biomarkers and were developed from small case-control studies.  The model by 
Han et al 2008 includes 5 genes (BANK1, B-cell scaffold protein with ankyrin repeats 1; 
BCNP1, B-cell novel protein 1; CDA, cytidine deaminase; MGC20553, FERM domain 
containing 3; MS4A, membrane-spanning 4 domains) identified from a case-control study 
including 58 patients with CRC and 57 disease-free controls using hierarchical cluster 
analysis and logistic regression(45). In that development population the biomarker panel has 
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an AUROC of 0.88 (95%CI: 0.81-0.94). It has yet to be externally validated.  The model 
developed by Marshall et al 2010 includes seven genes (ANXA3, Annexin A3; CLEC4D, C-
type lectin domain family4, member D; IL2RB, Interleukin 2 receptor, beta; LMNB1, Lamin 
B1; PRRG4, Proline risk Gla 4; TNFAIP6, tumour necrosis factor, alpha-induced protein 6; 
VNN1, Vanin 1) similarly identified from a case-control study with 112 patients with CRC 
and 120 disease-free controls from hospitals in Canada and the USA(49).  In that population 
the model has an AUROC of 0.80 (95%CI: 0.74-0.85) and in a separate sample of 99 patients 
with CRC and 111 controls in Malaysia the AUROC was reported as 0.76 (95%CI: 0.70-
0.82). The third risk model based entirely on genetic biomarkers also has acceptable 
discrimination.  It was developed by Wang et al in Taiwan, again from a case-control study, 
and includes 16 SNPs from a GWAS study in Asian people(51). It has an AUROC of 0.77 in 
the development population and 0.72 in cross-validation.  
The final group of four risk models including both genetic biomarkers and phenotypic 
variables, however, do not have such good discrimination and adding variable numbers of 
different SNPs to data available from self-completed questionnaires does not appear to 
improve discrimination. The addition of 10 SNPs to age, gender and family history(43) or 
three SNPs to age and family history(46) in case-control studies does not improve 
discrimination over age, gender and family history alone(50) (AUROC 0.57 and 0.73 
(95%CI: 0.68-0.77) (male), 0.65 (95%CI: 0.62-0.68) (female) compared to 0.67). The 
discrimination of a model with 14 SNPs added to BMI, smoking, alcohol, fibre intake, red 
meat intake and physical activity(54) has an AUROC of 0.63 in a simulated population which 
is no better than those models using only routinely available data in cross-sectional or cohort 
studies.  
 
Calibration of the risk models 
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Calibration was reported for 21 of the 52 models. In most cases it was reported as the 
Hosmer-Lemeshow statistic (n=9) or Chi-squared test (n=6) with p values ranging from 
p=0.0003 to p=0.94. Where expected:observed ratios were given the confidence intervals all 
cross one except for the model by Ma et al 2010 for colon cancer where it is 1.19 (95%CI: 
1.03-1.37)(38).    
 
Sensitivity and specificity of the risk models 
Sensitivity and specificity were reported for only seven models.  Two of these were 
the genetic models developed by Han and Marshall which have sensitivities of 88% and 
71.7% and specificities of 64% and 71.2% in external populations respectively(45, 49).  The 
other five were all risk models for advanced colorectal neoplasia and range from high 
sensitivity (92.4%) and low specificity (13.9%) in Kaminski(26) to low sensitivity (40%) and 
high specificity (93%) in Stegeman(29). 
 
Comparison of different outcomes  
Five studies(31, 36, 38, 37, 39) simultaneously developed risk models for more than 
one of advanced colorectal neoplasia, CRC, colon cancer and rectal cancer.  All showed that 
beta-coefficients and included variables differed slightly between different sites but only two 
provided any comparative data. Tao reported the performance of the same model for 
predicting advanced colorectal neoplasia or CRC and showed that the discrimination was 
similar (AUROC 0.68 for advanced colorectal neoplasia and 0.66 for CRC)(31).  Driver 
showed that the AUROC of a predictive model developed for colon cancer was only slightly 
superior to the model developed for CRC when predicting CRC risk (0.717 vs 0.695), but the 
goodness-of-fit test showed it to perform less well than the CRC model (Hosmer-Lemeshow 
statistic 0.43 vs 0.91)(36). 
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DISCUSSION 
Principal findings 
 To our knowledge this is the first comprehensive systematic review of risk prediction 
models for CRC.  It shows that multiple risk models exist for predicting the risk of 
developing CRC, colon cancer, rectal cancer or advanced colorectal neoplasia in 
asymptomatic populations, and that they have the potential to identify individuals at high risk 
of disease.  The discrimination of the models, as measured by AUROC, compare favourably 
with risk models used for other cancers, including breast cancer(55) and melanoma(56), and 
several include only variables recorded in routine medical records and so could be 
implemented into practice without the need for further data collection. Grouping risk models 
according to type and number of variables included (Figure 2) also shows that there is no 
clear improvement in discrimination as increasing numbers of variables are added from self-
completed questionnaires to routine data, or in studies in which genetic biomarkers are added 
to data from self-completed questionnaires.  A small number of risk models developed from 
case-control studies of genetic biomarkers alone show some promise but require further 
external validation in population-based samples. 
 
Strengths and weaknesses 
The main strength of this review is our use of a broad search strategy and careful 
screening of possible papers for inclusion. Whilst we cannot exclude publication bias or the 
possibility that there are other risk models that we did not identify, using this systematic 
approach enabled us to identify over 3 times as many risk models as reported in previous 
reviews in this area(8, 9).  This review is, therefore, the most comprehensive to date and the 
inclusion of less well cited risk models allows us to demonstrate for the first time the relative 
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performance of simple and more complex models.   However, as we included only those risk 
models applicable to asymptomatic individuals from the general population, these models are 
not applicable to those with familial syndromes, such as Lynch syndrome or familial 
adenomatous polyposis, or those with existing cancer. Most of the risk models were 
developed from predominantly white populations in Europe or America or Asian populations 
in China, Japan, Taiwan and Korea, with only two from Arabic countries and none from 
Australasia. There is a well-recognized high degree of heterogeneity by nationality in CRC 
incidence with an up to 10-fold difference internationally(57). Much of this variation is 
thought to be due to differences in environmental risk factors as the incidence rate of CRC in 
migrants approaches that of the host country within one or two generations(58).  The risk 
models in this review may, therefore, be less applicable to these less well represented 
populations.  
 
Implications for clinicians and policy makers 
  There is now substantial evidence that the incidence of, and mortality from, CRC can 
be reduced by screening with faecal occult blood testing(59–61), flexible sigmoidoscopy(62, 
63), or colonoscopy(64–66), and multiple economic analyses support the cost-effectiveness 
of population-based CRC screening(67–69).  This review shows that risk models exist that 
have the potential to stratify the general population into risk categories and allow screening 
and preventive strategies to be targeted at those most likely to benefit whilst leaving those at 
low risk of disease unexposed to direct and indirect harms of screening programmes. This 
might improve the cost-effectiveness of CRC screening(70) and would address concerns 
about demand and capacity for colonscopy(71, 72).  It would also provide an opportunity to 
implement potential chemo-preventive medications such as non-steroidal anti-inflammatory 
drugs. These drugs are currently not recommended for asymptomatic adults at average risk 
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for CRC(73), but both the United States Preventive Services Task Force(74) and a recent 
international consensus panel(75) advocate additional research into the use of aspirin in high-
risk individuals  for whom benefits might outweigh the harms.  The use of risk prediction 
models would also potentially increase uptake of screening and provide an opportunity to 
give information to encourage lifestyle changes. Despite the known mortality benefit of CRC 
screening, large numbers of eligible people do not participate in CRC screening programs(76, 
77). Whilst the reasons for non-participation are complex, several studies have suggested that 
high-risk individuals are more likely to be up-to-date with CRC screening and adhere to 
physician recommendations(77–80). Knowledge of their risk, both within or outside 
screening programmes, may also encourage adoption of more healthy lifestyles which might 
further improve outcomes: it is estimated that between 30% and 70% of the overall burden of 
colon cancers in the US and UK populations could be prevented through moderate changes in 
diet and lifestyle(81, 82), and information about individualised colon cancer risk has been 
shown to lead to a reduction in multiple behavioural risk factors in patients with a history of 
colon adenoma(83). 
   Several barriers, however, exist to the incorporation of risk prediction models into 
practice.  The main one is the practical challenge of collecting the necessary risk factor 
information.  Many of the included risk scores used data collected from food frequency 
questionnaires. Whilst this allows accurate estimates for research, their application is unlikely 
to be practical at the population level.  Similarly, risk scores including genetic biomarkers 
require sample collection and processing and some means of feeding back results to 
individuals. Although from figure 2 it appears as if the two models with the highest reported 
discrimination were both based on genes, these were developed in small case-control studies 
which will tend to over-estimate performance in the general population. Several risk models 
including genetic biomarkers also performed no better than those based on routine 
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information and GWA studies of colorectal cancer have shown that the CRC risks associated 
with each of the variants are at best modest (relative risks of 1.1-1.3), with the distribution of 
risk alleles following a normal distribution in both CRC cases and controls(84). As our 
understanding of these genetic biomarkers increases, and point-of-care genetic profiling 
becomes more widely available, more accurate models incorporating genomic markers will 
become easier to implement. A risk model that is able to predict CRC, colon cancer, rectal 
cancer and advanced colorectal neoplasia would also clearly have more utility in the clinical 
setting than separate models for each and this review also shows that to be possible: where 
studies developed separate risk models for different sites, the final models did include 
different variables, but these differences tended to be small and the performance of the 
models similar(31, 36).     
 
Unanswered questions and future research 
Whilst the potential clinical and economic benefits of successfully integrating a risk 
prediction model for CRC into clinical practice could be substantial, it remains to be defined 
what role the currently available and emerging models can have in practice and a number of 
steps are required to establish a viable useable risk profile. Firstly, this review provides 
comparative data on the performance of existing risk models but ideally the choice of risk 
model for each country would be based on validation studies in each population of 
interest(10). Further studies are therefore needed to compare the performance of these risk 
models, including those for different sites, simultaneously in large cohorts. This is 
particularly the case for those risk models incorporating genetic biomarkers which have 
mostly been developed using small case-control studies and which may perform substantially 
less well in population-based studies.  Secondly, research is needed to establish the optimal 
implementation strategies. This includes modelling studies comparing the impact on 
16 
 
morbidity and mortality and cost-effectiveness of different implementation strategies in 
comparison to current programmes based on age alone and consensus meetings with expert 
groups. Thirdly, qualitative research with members of the public and practitioners is needed 
to determine how best to communicate the risk output and to assess the feasibility, 
acceptability of any risk based programme. Finally, before any risk model is introduced into 
routine clinical practice, implementation studies, ideally randomised controlled trials, are 
needed to assess the benefits and potential adverse consequences of applying these models in 
practice.  
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Table 1. Summary of 52 risk models. 
Author, 
year Country Outcome Factors included in score Factors considered but not included 
TRIPOD 
level* Data source 
Betes 
2003a (21) 
Spain ACN + Age, gender, BMI NSAIDs, nonspecific abdominal pain, bowel habit (1-2 
movements/day; diarrhoea-alternate; chronic constipation), 
cholesterol, triglycerides, form of recruitment 
1a Medical records 
Betes 
2003b (21) 
Spain ACN Age, gender, BMI NSAIDs, nonspecific abdominal pain, bowel habit (1-2 
movements/day; diarrhoea-alternate; chronic constipation), 
cholesterol, triglycerides, form of recruitment 
1a, 4 Medical records 
Cai 2012 
(22) 
China ACN Age, gender, smoking, diabetes mellitus, green vegetables, 
pickled food, fried food, white meat 
BMI, hypertension, hypertriglyceridaemia, alcohol intake, 
calcium or vitamin D supplementation, aspirin or NSAIDs, fresh 
fruit, eggs, milk, red meat 
2a, 4 Questionnaire 
Chen 2013 
(23) 
China ACN Age, smoking, alcohol Gender, history of CVD, egg intake, defaecation frequency, 
education level, hypertension, diabetes, hyperlipidaemia, gastric / 
gallbladder / appendix operations history, aspirin, tea drinking, 
physical activity, green vegetable / fruit / milk / pickled food / 
fried or smoked food / bamboo root / red meat / white meat 
intake 
1b Medical records 
Chen 2014 
(24)  
China ACN Age, gender, history of CHD, egg intake, defaecation frequency Education level, hypertension, diabetes, hyperlipidaemia, gastric/ 
gallbladder / appendix operations history, aspirin use, smoking, 
alcohol, tea drinking, physical activity, green vegetable / fruit / 
milk / pickled food / fried or smoked food / bamboo root / red 
meat intake / white meat intake 
1b Questionnaire 
Hassan 
2013 (25) 
Italy ACN Age, gender Family history, BMI 1b Medical records 
Kaminski 
2014 (26) 
Poland ACN Age, gender, BMI, smoking, number and age affected of first 
degree relatives with CRC  
Diabetes, regular aspirin use 2a Questionnaire 
Lin 2006 
(27) 
USA ACN Age, gender, first degree relative with CRC or second degree 
relative with adenoma 
None 1a, 4 Questionnaire 
Lin 2013 
(28) 
USA ACN Age, BMI, smoking, number of first degree relatives with CRC, 
previous sigmoidoscopy or colonoscopy, polyp history in past 
10 years, physical activity, vegetable consumption, NSAID use, 
oestrogen use 
None 1b Questionnaire 
Stegeman 
2013 (30) 
Netherlands ACN Age, gender, BMI, first degree  relative with CRC, menopausal 
status (women), smoking, sleep, vigorous exercise, alcohol, 
fibre intake, calcium intake, red meat intake, aspirin/NSAID use 
None 1a Questionnaire 
Stegeman 
2014 (29) 
Netherlands ACN Age, smoking, first degree relative with CRC, faecal 
immunochemical test, calcium intake 
BMI, menopausal status, aspirin/NSAID use, fibre / red meat 
intake 
1a Questionnaire 
Tao 2014a 
(31) 
Germany ACN Age, gender, smoking, first-degree relative with CRC, alcohol, 
previous polyp, red meat consumption, NSAIDS, previous 
colonoscopy 
BMI, physical activity, vegetable / fruit intake, HRT 3 Questionnaire 
Yeoh 2011 
(32) 
Asia ACN Age, gender, smoking, first degree relative with CRC Alcohol, diabetes 3 Questionnaire 
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Almurshed 
2009 (33) 
Saudi 
Arabia 
CC Region, marital status, education level, employment status, 
activity level, physical activity, knowledge of high-fibre diet 
None 1a Questionnaire 
Camp 
2002 (34) 
USA CC Age, BMI, first degree relative with CRC, NSAID use, long 
term vigorous physical activity, Western diet, folic acid, 
calcium intake, lutein intake, refined grain intake, Prudent 
dietary pattern 
Sex, hormone replacement therapy, smoking history, calorific 
intake, dietary fibre, total vegetable / fat intake, glycaemic index 
of intake, mutagen index, alcohol consumption 
1a Questionnaire 
Colditz 
2000 (35) 
USA CC BMI, first degree relative with CRC, faecal occult blood test or 
sigmoidoscopy, aspirin, IBD, folate, vegetables, alcohol, height, 
physical activity, oestrogen replacement, fruits, fibre, saturated 
fat, smoking 
None 1a, 4 Questionnaire 
Driver 
2007a (36) 
USA CC Age, BMI, history of smoking Weekly or daily alcohol use, intake of vegetables, intake of 
multivitamins, vitamin C, vitamin E, intake of cold cereal, 
physical activity, history of diabetes
1a Medical records 
Ma 2010a 
(38) 
Japan CC Age, BMI, smoking, alcohol, physical activity FH CRC, diabetes 3 Questionnaire 
Wei E 
2009 (40) 
USA CC Age, BMI, smoking, current or past HRT, height, first degree 
relative with colon cancer, processed meat consumption, folate 
intake, physical activity, aspirin use, sigmoidoscopy or 
colonoscopy during follow up 
None 1a Questionnaire 
Wei E 
2004a (41) 
USA CC Age, gender, BMI, smoking, alcohol, first degree relative with 
colon cancer, physical activity, height, processed meat, servings 
of beef, pork or lamb, folate intake, calcium intake 
None 1a Questionnaire 
Shin 2014a 
(39) 
Korea CC (male) Age, BMI, family history of cancer, height, fasting serum 
glucose, total serum cholesterol, alcohol, meat consumption 
Smoking, exercise      3 Questionnaire 
and blood test 
Shin 
2014d (39) 
Korea CC (female) Age, family history of cancer, height, fasting serum glucose, 
meat consumption 
BMI, alcohol, smoking, exercise, female reproductive factors 3 Questionnaire 
and blood test 
Freedman 
2009b (37) 
USA Distal CC 
(male) 
BMI, number of first degree relatives with CRC, prior negative 
sigmoidoscopy/colonoscopy, polyp history, aspirin and NSAID 
use 
FOBT, multivitamin use, red meat / fruit / vegetable intake,  
alcohol intake, physical activity, smoking,  age 
1a, 4** Questionnaire 
Freedman 
2009e (37) 
USA Distal CC 
(female) 
Age, BMI, number of relatives with CRC, prior negative 
sigmoidoscopy/colonoscopy, polyp history, aspirin and NSAID 
use, oestrogen use in last 2 years 
FOBT, multivitamin use, red meat / fruit / vegetable intake,  
alcohol intake, physical activity 
1a, 4** Questionnaire 
Freedman 
2009a (37) 
USA Proximal CC 
(male) 
BMI, smoking,, number of first degree relatives with CRC, 
prior negative sigmoidoscopy/colonoscopy, polyp history, 
aspirin and NSAID use, vegetable consumption 
FOBT, multivitamin use, red meat / fruit intake,  alcohol intake, 
physical activity, age 
1a, 4** Questionnaire 
Freedman 
2009d (37) 
USA Proximal CC 
(female) 
Number of first degree relatives with CRC, prior negative 
sigmoidoscopy/colonoscopy, polyp history, physical activity, 
aspirin and NSAID use, vegetable consumption, oestrogen use 
in last 2 years 
FOBT, multivitamin use, red meat / fruit intake,  alcohol intake, 
BMI, age 
1a, 4** Questionnaire 
Bener 
2010 (42) 
Qatar CRC BMI, smoking, family history of CRC, consumption of bakery 
products, consumption of soft drinks 
Smoking of Sheesha, fresh fruit / fresh vegetable / green salad / 
frozen meat/chicken / fast food / processed food intake, 
consanguinity 
1a Questionnaire 
Driver 
2007b (36) 
USA CRC Age, BMI, history of smoking, weekly or daily alcohol use Intake of vegetables, intake of multivitamins, vitamin C, vitamin 
E, intake of cold cereal, physical activity, history of diabetes 
 
1b Medical records 
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Dunlop 
2013 (43) 
Worldwide CRC Age, gender, first degree relative with CRC, 10 SNPs1 None 3 Questionnaire 
and blood test 
for genetics 
Guesmi 
2010 (44) 
Tunisia CRC Age, meat consumption, milk consumption Gender, anaemia, smoking, physical activity, fruit / fried food 
intake, urban or rural living, olive oil consumption, walking 
1a Questionnaire 
Han 2008 
(45) 
Not given CRC 5 genes2  Affymetrix U133Plis 2.0 chip 3 Blood test for 
genetics 
Johnson 
2013 (47) 
Worldwide CRC BMI, smoking, first degree relative with CRC, physical activity, 
alcohol, IBD, hormone therapy (current or former), 
aspirin/NSAIDs, processed meat / red meat / fruit / vegetable 
intake 
None 1a Questionnaire 
Lubbe 
2012 (48) 
UK CRC 14 SNPs3 None 1a Blood test for 
genetics 
Ma 2010c 
(38) 
Japan CRC Age, BMI, smoking, physical activity, alcohol FH CRC, diabetes 3 Questionnaire 
Marshall 
2010 (49) 
Canada and 
USA 
CRC 7 genes4 38 genes 2b Blood test for 
genetics 
Tao 2014b 
(31) 
Germany CRC Age, gender, smoking, first-degree relative with CRC, alcohol, 
previous polyp, red meat consumption, NSAIDS, previous 
colonoscopy 
BMI, physical activity, vegetable / fruit intake, HRT 3 Questionnaire 
Taylor 
2011 (50) 
USA CRC Age, first, second and third degree relatives with CRC None 1a Questionnaire 
Wang 
2013 (51) 
Taiwan CRC 16 SNPs5 10 additional SNPs 1b Blood test for 
genetics 
Yarnall 
2013 (54) 
UK data CRC BMI, smoking, alcohol, fibre intake, red meat intake, physical 
activity, 14 SNPs6 
None 1a Questionnaire 
and blood test 
for genetics 
Wei Y 
2009 (52) 
China CRC BMI, smoking, first or second degree relative with CRC,  
alcohol 
None 1a Questionnaire 
Shin 2014c 
(39) 
Korea CRC (male) Age, BMI, family history of cancer, height, fasting serum 
glucose, total serum cholesterol, alcohol, meat consumption 
Smoking, exercise      3 Questionnaire 
and blood test 
Wells 
2014b (53) 
California 
and Hawaii 
CRC (male) Age, BMI, smoking, first degree relative with CC, 
race/ethnicity,  alcohol, years of education, regular use of 
aspirin, multivitamins, red meat intake, history of diabetes, 
physical activity 
History of cancer, regular use of NSAIDs, preference for well-
done meat 
1b Questionnaire 
Jo 2012b 
(46) 
Korea CRC (male) 3 SNPs7, age, family history of CRC From 426,019 SNPs 1b Questionnaire 
and blood test 
for genetics 
Shin 2014f 
(39) 
Korea CRC (female) Age, family history of cancer, height, fasting serum glucose, 
meat consumption 
BMI, alcohol, smoking, exercise, female reproductive factors 3 Questionnaire 
and blood test 
Wells 
2014a (53) 
California 
and Hawaii 
CRC (female) Age, BMI, smoking, first degree relative with CC, 
race/ethnicity,  alcohol, years of education, regular use of 
NSAIDs,  multivitamins, history of diabetes, use of oestrogen 
Preference for well done meat, physical activity, regular use of 
aspirin, red meat intake, history of cancer 
1b Questionnaire 
Jo 2012a Korea CRC (female) Age, family history of CRC, 5 SNPs8 From 426,019 SNPs 1b Questionnaire 
31 
 
(46) and blood test 
for genetics 
Ma 2010b 
(38) 
Japan Rectal cancer Age, BMI, physical activity, alcohol FH CRC, diabetes, smoking 3 Questionnaire 
Wei E 
2004b (41) 
USA Rectal cancer Age, BMI, smoking, first degree relative with rectal cancer, 
alcohol, physical activity, height, processed meat, gender, 
servings of beef, pork or lamb, folate intake, calcium intake 
None 1a Questionnaire 
Freedman 
2009c (37) 
USA Rectal cancer 
(male) 
Number of first degree relatives with CRC, prior negative 
sigmoidoscopy/colonoscopy, polyp history, NSAID use, 
physical activity 
FOBT, multivitamin use, red meat / fruit / vegetable intake,  
alcohol intake, smoking, BMI, age 
1a, 4* Questionnaire 
Shin 
2014b (39) 
Korea Rectal cancer 
(male) 
Age, BMI, family history of cancer, height, fasting serum 
glucose, total serum cholesterol, alcohol, meat consumption 
Smoking, exercise      3 Questionnaire 
and blood test 
Freedman 
2009f (37) 
USA Rectal cancer 
(female) 
BMI, number of first degree relatives with CRC, prior negative 
sigmoidoscopy/colonoscopy, polyp history, physical activity,  
NSAID use, oestrogen use in last 2 years 
FOBT, multivitamin use, red meat / fruit / vegetable intake,  
alcohol intake, age 
1a, 4* Questionnaire 
Shin 2014e 
(39) 
Korea Rectal cancer 
(female) 
Age, family history of cancer, height, fasting serum glucose, 
meat consumption 
BMI, alcohol, smoking, exercise, female reproductive factors 3 Questionnaire 
and blood test 
* Types of prediction model studies for each model defined according to the TRIPOD guidelines. 1a – Development only; 1b – Development and validation using resampling; 2a – Random split-sample 
development and validation; 2b – Nonrandom split-sample development and validation; 3 – Development and validation using separate data; 4 – Validation study 
** The validation was for colon and rectal cancer combined 
ACN+ - advanced colorectal neoplasia including moderate dysplasia 
ACN – advanced colorectal neoplasia 
CC – colon cancer 
CRC – colorectal cancer 
BMI – body mass index 
NSAIDs – non-steroidal anti-inflammatory drugs 
CVD – cardiovascular disease 
CHD – coronary heart disease 
HRT – hormone replacement therapy 
IBD – inflammatory bowel disease 
FOBT – faecal occult blood test 
FH – family history 
 
1 rs6983267, rs4779584, rs4939827, rs3802842, rs10795668, rs16892766, rs4444235, rs9929218, rs10411210, rs961253 
2BANK1,B-cell scaffold protein with ankyrin repeats 1; BCNP1,B-cell novel protein 1; CDA, cytidine deaminase; MGC20553, FERM domain containing 3; MS4A, membrane-spanning 4 domains 
314 SNPs localizing to 14 chromosome regions – 1q41, 3q26.2, 8q23.3, 8q24.21, 10p14, 11q23.1, 12q13.13, 14q22.2, 15q13.3, 16q22.1, 18q21.1, 19q13.11, 20p12.3, 20q13.33 
4ANXA3, Annexin A3; CLEC4D, C-type lectin domain family4, member D; IL2RB, Interleukin 2 receptor, beta; LMNB1, Lamin B1; PRRG4, Proline risk Gla 4; TNFAIP6, Tumour necrosis factor, alpha-induced 
protein 6; VNN1, Vanin 1 
5 rs1983891, rs869736, rs3214050, rs10411210, rs3731055, rs231775, rs1412829, rs1572072, rs6983267, rs1799782, rs712221, rs160277, rs11721827, rs2736100, rs3135967, rs1760944 
6 rs6691170, rs10936599, rs16892766, rs6983267, rs10795668, rs3802842, rs11169552, rs4444235, rs4779584, rs9929218, rs4939827, rs10411210, rs961253, rs4925386 
7 rs17391002, rs9549448, rs254833 
8 rs10083736, rs16987827, rs8046516, rs9926182, rs175237
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Table 2. 87 Risk factors (excluding genes and SNPs) considered across all included studies 
Personal characteristics 
Age  
BMI 
Gender 
Consanguinuity 
Family history of colorectal cancer 
Height 
Race / ethnicity 
Marital status 
Education level 
Employment status 
Knowledge of high-fibre diet 
Years of education 
Urban or rural living 
 
Personal medical history 
Gastric operation history 
Gallbladder operation history 
Appendix operations 
Hypertension 
Diabetes or history of diabetes 
Inflammatory bowel disease 
History of coronary heart disease 
History of cardiovascular disease 
Polyp history 
History of cancer 
Defaecation frequency 
Non-specific abdominal pain 
 
Female hormonal factors 
HRT (ever, current or past) 
Oestrogen use 
Menopausal status 
Age at menarche 
Age at first childbirth 
Age at menopause 
 
Lifestyle 
Smoking (tobacco or Sheesha) 
Alcohol 
Physical activity 
Sleep 
 
Drug and vitamin supplementation 
NSAID use 
Aspirin use 
Multivitamin use 
Calcium supplementation 
Vitamin D supplementation 
Vitamin C supplementation 
Vitamin E supplementation 
Diet 
Fibre intake 
Meat 
Red meat 
Processed meat 
Servings of beef, pork or lamb 
White meat 
Frozen meat/chicken 
Preference for well-done meat 
Vegetables 
Fresh vegetables 
Green vegetables 
Green salad 
Fruit 
Fast food 
Processed food 
Pickled food 
Fried food 
Smoked food 
Eggs 
Milk 
Fat 
Saturated fat 
Bakery products 
Refined grain 
Tea 
Olive oil 
Soft drinks 
Bamboo root intake 
Cold cereal 
Glycaemic index of intake 
Western diet 
Prudent dietary pattern 
Calorific intake 
Mutagen index*  
Calcium intake 
Folic acid intake 
Lutein intake 
 
Biomarkers 
Fasting glucose 
Hyperlipidaemia 
Cholesterol 
Triglycerides 
Haemoglobin 
 
Other tests 
Faecal immunochemical test 
Faecal occult blood test 
Prior sigmoidoscopy or colonoscopy 
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Table 3. Details of performance of models 
Author, 
year Outcome 
Performance in development 
population 
Performance in bootstrap or cross-
validation 
Performance in sub-set of population Performance in external population 
Discrimination 
AUROC 
(95% CI) 
Calibration Accuracy 
Discrimination 
AUROC 
(95% CI) 
Calibration Accuracy 
Discrimination 
AUROC 
(95% CI) 
Calibration Accuracy 
Discrimination 
AUROC 
(95% CI) 
Calibration Accuracy External reference 
Betes 
2003a (21) ACN+ 0.65  
PPV 12.0-
50.0          
 
Betes 
2003b 
(21) 
ACN 0.67  PPV 7.3-33.3       
0.65 
(0.61-0.69)   
Cai 2012 
(22) 
0.71 
(0.64-0.78)   
Chen 
2014 (24) 
Cai 2012 
(22) ACN 
0.74 
(0.72-0.77)  
Sens 82.8; 
Spec 50.8 
0.74 
(0.72-0.77)   
0.74 (0.70-
0.78) H-L p=0.77 
Sens 80.3; 
Spec 51.2 
0.65 
(0.58-0.72)   
Chen 
2014 (24) 
Chen 2013 
(23) ACN 
0.65 
(0.61-0.69) 
H-L 
p=0.093 
Sens 65.1; 
Spec 57.2; 
PPV 44.4; 
NPV 75.7
0.66 
(0.62-0.68)          
Chen 2014 
(24) ACN 
0.75 
(0.69-0.82) 
H-L 
p=0.205 
Sens 93.8; 
Spec 47.6; 
PPV 9.1; 
NPV 99.3 
0.75 
(0.70-0.82)          
Hassan 
2013 (25) ACN     
H-L 
p=0.30         
Kaminski 
2014 (26) ACN 0.64* 
H-L 
p=0.74*     
0.62 (0.60-
0.64) 
E/O ratio 1 
(0.95-1.06). 
H-L 
p=0.16* 
Sens 92.4, 
Spec 13.9, 
PPV 7.55, 
NPV 96.0; 
    
Lin 2006 
(27) ACN 
 
 
 
 
 
 
 
 
0.65 
(0.61-0.70)   
Cai 2012 
(22) 
0.71 
(0.64-0.77)   
Chen 
2014 (24) 
Lin 2013 
(28) ACN    
Men 0.61 
(0.58-0.65), 
Women 0.62 
(0.58-0.66) 
         
Stegeman 
2014 (29) ACN 0.76 
H-L 
p=0.94 
Sens 40; 
Spec 93           
Tao 2014a 
(31) ACN 
0.67 
(0.65-0.69) 
H-L 
p=0.21        
0.66 
(0.63-0.69) H-L p=0.65  
Tao 2014 
(31) 
Yeoh 
2011 (32) ACN 
0.66 
(0.62-0.70) 
H-L 
p=0.29        
0.64 
(0.60-0.68) H-L p=0.49   
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Colditz 
2000 (34) CC  
 
       
Women 
0.67 (0.64-
0.70); Men 
0.71 (0.68-
0.74)** 
  
Kim 2004 
(17) 
 0.6   
Schroy 
2012 (19) 
Driver 
2007a (36) CC 0.72 
H-L 
p=0.43            
Ma 2010a 
(38) CC 
0.71 
(0.68-0.74)         
0.66(0.62-
0.70) 
χ2 p=0.20; 
E/O 1.19 
(1.03-1.37) 
 Ma 2010 (38) 
Wei E 
2009 (40) CC 
0.61 
(0.59-0.63)             
Shin 
2014a (39) CC (male) 
0.77 
(0.76-0.78) χ
2 p=0.22        0.77 (0.75-0.79) χ
2 p=0.029   
Shin 
2014d 
(39) 
CC 
(female) 
0.71 
(0.69-0.73) χ
2 p=0.73        0.72 (0.70-0.74) χ
2 p=0.49   
Driver 
2007b 
(36) 
CRC 0.70 H-L p=0.91  0.69          
Dunlop 
2013 (43) CRC    0.59  
PPV 
0.71; 
NPV 
0.51 
   0.57   
Dunlop 
2013 (43) 
Han 2008 
(45) CRC 
0.88 
(0.81-0.94)  
Sens 94; 
Spec 77 
PPV 82, 
NPV 92 
  
79% 
(71.5-
86.5) 
     
Sens 88; 
Spec 64. 
PPV 67; 
NPV 87 
 
Ma 2010c 
(38) CRC 
0.70 
(0.68-0.72)         
0.64 (0.61-
0.67) 
χ2 p=0.08; 
E/O 1.09 
(0.98-1.23) 
 Ma 2010 (38) 
Marshall 
2010 (49) CRC 
0.80 
(0.74-0.85)  
Sens 82; 
Spec 64; 
PPV 68, 
NPV 79
   0.80 (0.76-0.84)  
Sens 72; 
Spec 70; 
PPV 70, 
NPV 72
0.76 
(0.70-0.82)  
Sens 
71.7; 
Spec 
71.2
Yip 2010 
(20) 
Tao 2014b 
(31) CRC 
0.71 
(0.67-0.75)         
0.68 
(0.57-0.79)   
Tao 2014 
(31) 
Taylor 
2011 (50) CRC 0.67             
Wang 
2013 (51) CRC 0.77   0.72          
Yarnall 
2013 (54) CRC 
0.63 
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Freedman 
2009a,b,c 
(37) 
CRC 
(male)          
0.61 
(0.60-0.62) 
E/O ratio 
0.99 
(0.96-1.04) 
 Park 2008 (18) 
Jo 2012b 
(46) 
CRC 
(male) 
0.73 
(0.68-0.77)   
0.70 
(0.65-0.74)          
Shin 
2014c (39) 
CRC 
(male) 
0.76 
(0.76-0.77) 
χ2 
p=0.1035        
0.78 
(0.77-0.79) χ
2 p=0.0003   
Wells 
2014b 
(53) 
CRC 
(male) 0.69   
0.68 
(0.67-0.69)          
Freedman 
2009d,e,f 
(37) 
CRC 
(female)          
0.61 
(0.59-0.62) 
E/O ratio 
1.05 
(0.98-1.11) 
 Park 2008 (18) 
Jo 2012a 
(46) 
CRC 
(female) 
0.65 
(0.62-0.68)   
0.60 
(0.56-0.64)          
Shin 
2014f (39) 
CRC 
(female) 
0.71 
(0.70-0.72) 
χ2 
p=0.6123        
0.73 
(0.71-0.74) χ
2 p=0.1569   
Wells 
2014a (53) 
CRC 
(female) 0.69   
0.68 
(0.67-0.69)          
Ma 2010b 
(38) 
Rectal 
cancer 
0.68 
(0.64-0.71)         
0.62 (0.57-
0.66) 
χ2 p=0.19; 
E/O 0.94 
(0.78-1.12) 
 Ma 2010 (38) 
Shin 
2014b 
(39) 
Rectal 
cancer 
(male) 
0.75 
(0.74-0.76) χ
2 p=0.29        0.78 (0.77-0.79) χ
2 p=0.0003   
Shin 
2014e (39) 
Rectal 
cancer 
(female) 
0.70 
(0.68-0.71) 
χ2 
p=0.084        
0.72 
(0.70-0.74) χ
2 p=0.198   
ACN+ Advanced colorectal neoplasia including moderate dysplasia 
ACN – advanced colorectal neoplasia defined as invasive cancer, an adenoma 10mm or more, a villous adenoma (at least 25% villous) or an adenoma with high grade dysplasia 
CC – colon cancer 
CRC – colorectal cancer 
AUROC – area under the receiver operator curve. Values given as mean and 95% confidence intervals 
Sens – sensitivity 
Spec – specificity 
PPV – positive predictive value 
NPV – negative predictive value 
H-L – Hosmer-Lemeshow test 
E/O – Expected over observed ratio 
* These values are from the model prior to conversion of the coefficients to scores (Kaminski)        
** Removed aspirin use from men and history of chronic IBD from both genders as not available so actually not validating original score   
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FIGURE LEGENDS 
Figure 1. PRISMA flow diagram 
Figure 2. Relative discriminative performance of the risk scores ordered by number and 
complexity of variables included 
 


